Biomea Fusion, Inc.(BMEA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BMEA Biomea Fusion, Inc.

Pre-Market Trading 12-24 07:20:35 EST

4.03

-0.20

-4.73%

盘前3.89

-0.14-3.47%

04:21 EST

High4.29	Low4.01	Vol602.62K
Open4.21	D1 Closing4.23	Amplitude6.62%
Mkt Cap146.04M	Tradable Cap90.49M	Total Shares36.24M
T/O2.45M	T/O Rate2.68%	Tradable Shares22.46M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BMEA","market":"US","secType":"STK","nameCN":"Biomea Fusion, Inc.","latestPrice":4.03,"timestamp":1734987600000,"preClose":4.23,"halted":0,"volume":602621,"hourTrading":{"tag":"盘前","latestPrice":3.89,"preClose":4.03,"latestTime":"04:21 EST","volume":100,"amount":389,"timestamp":1735032081087},"delay":0,"floatShares":22455084,"shares":36238687,"eps":-4.002201,"marketStatus":"Pre-Market Trading","change":-0.2,"latestTime":"12-24 07:20:35 EST","open":4.21,"high":4.29,"low":4.01,"amount":2452900.6843270003,"amplitude":0.066194,"askPrice":4.19,"askSize":13,"bidPrice":3.92,"bidSize":90,"shortable":3,"etf":0,"ttmEps":-4.002201,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1735050600000},"marketStatusCode":1,"adr":0,"listingDate":1618545600000,"exchange":"NASDAQ","adjPreClose":4.03,"preHourTrading":{"tag":"盘前","latestPrice":3.89,"preClose":4.03,"latestTime":"04:21 EST","volume":100,"amount":389,"timestamp":1735032081087},"postHourTrading":{"tag":"盘后","latestPrice":4,"preClose":4.03,"latestTime":"19:55 EST","volume":5335,"amount":21522.8442,"timestamp":1735001709715},"volumeRatio":0.24660360994154332,"impliedVol":2.2491,"impliedVolPercentile":0.8765},"requestUrl":"/m/hq/s/BMEA/wiki","defaultTab":"wiki","newsList":[{"id":"2493005476","title":"Biomea Fusion Advances Diabetes Treatment with Positive Study Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2493005476","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493005476?lang=en_us&edition=fundamental","pubTime":"2024-12-21 04:27","pubTimestamp":1734726454,"startTime":"0","endTime":"0","summary":"The latest announcement is out from Biomea Fusion ( ($BMEA) ). Biomea Fusion announced positive topline results from its Phase II COVALENT-111 stud...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biomea-fusion-advances-diabetes-treatment-with-positive-study-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biomea-fusion-advances-diabetes-treatment-with-positive-study-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BMEA","BK4139","BK4585"],"gpt_icon":0},{"id":"2492127779","title":"Biomea Fusion Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2492127779","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492127779?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:08","pubTimestamp":1734613680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BMEA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 19, 2024 08:08 ET (13:08 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA"],"gpt_icon":0},{"id":"2492185612","title":"Biomea Fusion Inc : Scotiabank Cuts Target Price to $30 From $41","url":"https://stock-news.laohu8.com/highlight/detail?id=2492185612","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492185612?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:35","pubTimestamp":1734528909,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nFWN3NJ0NC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BMEA","BK4585","BK4539","BK4139"],"gpt_icon":0},{"id":"2492787905","title":"Barclays Remains a Hold on Biomea Fusion (BMEA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492787905","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492787905?lang=en_us&edition=fundamental","pubTime":"2024-12-18 18:36","pubTimestamp":1734518175,"startTime":"0","endTime":"0","summary":"Barclays analyst Peter Lawson maintained a Hold rating on Biomea Fusion (BMEA – Research Report) today and set a price target of $11.00. The compan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-hold-on-biomea-fusion-bmea?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/barclays-remains-a-hold-on-biomea-fusion-bmea?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","BK4539","BMEA"],"gpt_icon":0},{"id":"2492099354","title":"Biomea Fusion price target lowered to $50 from $60 at Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2492099354","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492099354?lang=en_us&edition=fundamental","pubTime":"2024-12-18 01:20","pubTimestamp":1734456014,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Biomea Fusion (BMEA) to $50 from $60 and keeps an Outperform rating on the s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biomea-fusion-price-target-lowered-to-50-from-60-at-oppenheimer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biomea-fusion-price-target-lowered-to-50-from-60-at-oppenheimer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMEA","OPY"],"gpt_icon":0},{"id":"2492960243","title":"Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2492960243","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492960243?lang=en_us&edition=fundamental","pubTime":"2024-12-17 23:41","pubTimestamp":1734450069,"startTime":"0","endTime":"0","summary":"On Tuesday, Biomea Fusion Inc.  revealed topline results from the ongoing COVALENT-111 study of icovamenib in patients with type 2 diabetes .Icovamenib was investigated in three different dosing arms with a primary follow-up after 26 weeks: Arm A at 100mg QD  for 8 weeks, Arm B at 100mg QD for 12 weeks, and Arm C at 100 mg QD for 8 weeks and 100mg BID  for 4 weeks.Also Read: FDA Removes Clinical Hold On Biomea Fusion’s Early-Stage Trials For Potential Diabetes Candidate. The study showed positive topline results at Week 26, demonstrating statistically significant and clinically meaningful reductions in HbA1c, the gold standard for assessing glycemic control in T2D.Patients who completed dosing per the protocol and were suboptimally controlled at baseline on one or more prior agents, icovamenib, showed meaningful reductions in HbA1c with statistical significance in all major categories.Within the mild age-related diabetes  and severe insulin-deficient diabetes  patients, the mean HbA1c ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/4r1ASjjN9k9MVF2vjRzbvg--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/3bf1a938df0d3f89190bfb6277268ae3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/4r1ASjjN9k9MVF2vjRzbvg--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/3bf1a938df0d3f89190bfb6277268ae3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-diabetes-drug-developer-biomea-154109548.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BMPRXQ63.HKD","BK4539","BK4585","IE00BMPRXN33.USD","BMEA","BK4141","IE00BMPRXR70.SGD","BK4139","BK4588","LU0348723411.USD"],"gpt_icon":1},{"id":"2492696889","title":"BRIEF-Biomea Fusion Announces Positive Topline Results From Ongoing Phase II COVALENT-111 Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2492696889","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492696889?lang=en_us&edition=fundamental","pubTime":"2024-12-17 22:12","pubTimestamp":1734444762,"startTime":"0","endTime":"0","summary":"BRIEF-Biomea Fusion Announces Positive Topline Results From Ongoing Phase II COVALENT-111 StudyDec 17 (Reuters) - Biomea Fusion Inc BMEA.O:BIOMEA FUSION ANNOUNCES POSITIVE TOPLINE RESULTS FROM ONGOING","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA5XWY3R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4585","BK4539","BMEA"],"gpt_icon":0},{"id":"2492954437","title":"Biomea Fusion Announces Positive Topline Results From Ongoing Phase Ii Covalent-111 Study in Patients With Type 2 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2492954437","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492954437?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:10","pubTimestamp":1734441000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA5XWY3R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4585","BMEA","BK4139"],"gpt_icon":0},{"id":"2492434954","title":"Biomea Fusion Inc - Icovamenib Meets Primary Endpoint With Significant Reduction in Hba1c","url":"https://stock-news.laohu8.com/highlight/detail?id=2492434954","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492434954?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:10","pubTimestamp":1734441000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA5XWY3R:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BMEA","BK4539","BK4585"],"gpt_icon":0},{"id":"2492295443","title":"Biomea Fusion Inc - Icovamenib Well-Tolerated With No Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2492295443","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492295443?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:10","pubTimestamp":1734441000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241217:nTUA5XWY3R:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BMEA","BK4139","BK4585","BK4539"],"gpt_icon":0},{"id":"2492954210","title":"Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes","url":"https://stock-news.laohu8.com/highlight/detail?id=2492954210","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492954210?lang=en_us&edition=fundamental","pubTime":"2024-12-17 21:10","pubTimestamp":1734441000,"startTime":"0","endTime":"0","summary":"Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient populationBest response achiev","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/17/2998241/0/en/Biomea-Fusion-Announces-Positive-Topline-Results-from-Ongoing-Phase-II-COVALENT-111-Study-in-Patients-with-Type-2-Diabetes.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4157","BMEA","BMI","BK4539","BK4585"],"gpt_icon":0},{"id":"2492226196","title":"Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492226196","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492226196?lang=en_us&edition=fundamental","pubTime":"2024-12-17 07:15","pubTimestamp":1734390900,"startTime":"0","endTime":"0","summary":"Tuesday, December 17, 2024 at 8:00 am ESTREDWOOD CITY, Calif., Dec.  16, 2024  (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated t","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/16/2997949/0/en/Biomea-Fusion-to-Host-Conference-Call-to-Announce-Topline-Results-from-Phase-II-COVALENT-111-Study-in-Patients-with-Type-2-Diabetes-T2D.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA","HST","BK4139","BK4588","BK4539","BK4585","BK4218","BK4181"],"gpt_icon":0},{"id":"2491669862","title":"Biomea Fusion Price Target Maintained With a $40.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2491669862","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491669862?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:42","pubTimestamp":1734352920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BMEA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2024 07:42 ET (12:42 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA"],"gpt_icon":0},{"id":"2491487661","title":"Biomea Fusion’s Innovative Diabetes Therapy Boosts Buy Rating with Promising Preclinical Data on Icovamenib","url":"https://stock-news.laohu8.com/highlight/detail?id=2491487661","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491487661?lang=en_us&edition=fundamental","pubTime":"2024-12-16 19:35","pubTimestamp":1734348939,"startTime":"0","endTime":"0","summary":"In a report released today, Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Biomea Fusion (BMEA – Research Report), with a price t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/biomea-fusions-innovative-diabetes-therapy-boosts-buy-rating-with-promising-preclinical-data-on-icovamenib?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/biomea-fusions-innovative-diabetes-therapy-boosts-buy-rating-with-promising-preclinical-data-on-icovamenib?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMEA"],"gpt_icon":0},{"id":"2491350939","title":"Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22Nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (Wcirdc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491350939","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491350939?lang=en_us&edition=fundamental","pubTime":"2024-12-13 06:02","pubTimestamp":1734040941,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241212:nTUAB0JSY8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BMEA","BK4585","BK4139","BK4539"],"gpt_icon":0},{"id":"2491350733","title":"Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2491350733","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491350733?lang=en_us&edition=fundamental","pubTime":"2024-12-13 06:02","pubTimestamp":1734040920,"startTime":"0","endTime":"0","summary":"In preclinical experiments, icovamenib enhanced beta cell function and responsiveness of human islets to GLP-1-based therapies. These effects were associated with an increase in the expression levels ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/12/2996557/0/en/Biomea-Fusion-Announces-Oral-and-Poster-Presentations-of-Icovamenib-at-the-22nd-World-Congress-on-Insulin-Resistance-Diabetes-Cardiovascular-Disease-WCIRDC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA","BK4139","BK4082","CSII","BK4588","IE00B66KJ199.SGD","IE00B7SZL793.SGD","BK4539","MOD","BK4585","LU2065731478.USD","IE0031619046.USD","BK4511","BK4124","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2490094000","title":"Cautious Outlook on Biomea Fusion: Hold Rating Amid Clinical and Financial Uncertainties","url":"https://stock-news.laohu8.com/highlight/detail?id=2490094000","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490094000?lang=en_us&edition=fundamental","pubTime":"2024-12-10 20:16","pubTimestamp":1733832986,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Eric Joseph has maintained their neutral stance on BMEA stock, giving a Hold rating today. Eric Joseph has given his Hold ratin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cautious-outlook-on-biomea-fusion-hold-rating-amid-clinical-and-financial-uncertainties?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cautious-outlook-on-biomea-fusion-hold-rating-amid-clinical-and-financial-uncertainties?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMEA"],"gpt_icon":0},{"id":"2490094708","title":"Biomea Fusion Price Target Maintained With a $40.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2490094708","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490094708?lang=en_us&edition=fundamental","pubTime":"2024-12-10 20:13","pubTimestamp":1733832780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/BMEA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 10, 2024 07:13 ET (12:13 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMEA"],"gpt_icon":0},{"id":"2490081217","title":"Biomea Fusion Reports Preliminary Data From Experimental Cancer Therapy Study; Shares Rise After Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2490081217","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490081217?lang=en_us&edition=fundamental","pubTime":"2024-12-10 06:43","pubTimestamp":1733784236,"startTime":"0","endTime":"0","summary":"Biomea Fusion  said late Monday that preliminary data from an ongoing phase I study of BMF-500 supports its potential as a \"transformative\" therapy for patients with FMS-like tyrosine kinase 3 mutated relapsed or refractory acute leukemia, a type of cancer.The investigational therapy demonstrated a \"favorable\" safety and tolerability profile in the trial, with no dose-limiting toxicities observed across all dose levels, the company said.\"Given the safety profile demonstrated to date, and the lack of myelosuppression, we think BMF-500 could be an excellent combination partner used in standard of care,\" Biomea Chief Executive Thomas Butler said in a statement.The company's shares were up 3.6% in after-hours activity.Price: 6.00, Change: +0.21, Percent Change: +3.63","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4585","BK4139","BMEA","BK4539"],"gpt_icon":0},{"id":"2490083961","title":"Biomea Fusion announces preliminary COVALENT-103 study data","url":"https://stock-news.laohu8.com/highlight/detail?id=2490083961","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490083961?lang=en_us&edition=fundamental","pubTime":"2024-12-10 05:05","pubTimestamp":1733778312,"startTime":"0","endTime":"0","summary":"Biomea Fusion (BMEA) announced preliminary data from the ongoing Phase I COVALENT-103 study evaluating BMF-500, the company’s investigational coval...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biomea-fusion-announces-preliminary-covalent-103-study-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biomea-fusion-announces-preliminary-covalent-103-study-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4585","BK4539","BMEA"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biomeafusion.com","stockEarnings":[{"period":"1week","weight":-0.3111},{"period":"1month","weight":-0.3742},{"period":"3month","weight":-0.4962},{"period":"6month","weight":-0.0944},{"period":"1year","weight":-0.7184},{"period":"ytd","weight":-0.7225}],"compareEarnings":[{"period":"1week","weight":-0.0199},{"period":"1month","weight":-0.0014},{"period":"3month","weight":0.0409},{"period":"6month","weight":0.0902},{"period":"1year","weight":0.2555},{"period":"ytd","weight":0.2512}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. Biomea Fusion, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.111851},{"month":2,"riseRate":0.333333,"avgChangeRate":0.070637},{"month":3,"riseRate":0.333333,"avgChangeRate":0.321728},{"month":4,"riseRate":0,"avgChangeRate":-0.21954},{"month":5,"riseRate":0.75,"avgChangeRate":0.245778},{"month":6,"riseRate":0.25,"avgChangeRate":0.039512},{"month":7,"riseRate":0.5,"avgChangeRate":-0.004694},{"month":8,"riseRate":0.75,"avgChangeRate":0.054176},{"month":9,"riseRate":0.25,"avgChangeRate":-0.024488},{"month":10,"riseRate":0.25,"avgChangeRate":-0.076889},{"month":11,"riseRate":0.5,"avgChangeRate":0.006178},{"month":12,"riseRate":0.25,"avgChangeRate":-0.172543}],"exchange":"NASDAQ","name":"Biomea Fusion, Inc.","nameEN":"Biomea Fusion, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Biomea Fusion, Inc.(BMEA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Biomea Fusion, Inc.(BMEA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Biomea Fusion, Inc.,BMEA,Biomea Fusion, Inc.股票,Biomea Fusion, Inc.股票老虎,Biomea Fusion, Inc.股票老虎国际,Biomea Fusion, Inc.行情,Biomea Fusion, Inc.股票行情,Biomea Fusion, Inc.股价,Biomea Fusion, Inc.股市,Biomea Fusion, Inc.股票价格,Biomea Fusion, Inc.股票交易,Biomea Fusion, Inc.股票购买,Biomea Fusion, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Biomea Fusion, Inc.(BMEA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Biomea Fusion, Inc.(BMEA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}